{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T17:18:18Z","timestamp":1790961498878,"version":"4.1.0"},"reference-count":66,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,10,19]]},"DOI":"10.7759\/cureus.30457","type":"journal-article","created":{"date-parts":[[2022,10,19]],"date-time":"2022-10-19T09:37:13Z","timestamp":1666172233000},"source":"Crossref","is-referenced-by-count":5,"title":["The Diagnostic Accuracy of Serum and Urine Human Epididymis Protein 4 (HE4) in Ovarian Cancer in 15,394 Subjects: An Updated Meta-Analysis"],"prefix":"10.7759","author":[{"given":"Neelam","family":"Nalini","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amit","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saumya","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bijeta","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aditya V","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jay","family":"Prakash","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shreshtha","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.20121","article-title":"Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths","volume":"61","author":"Siegel R","year":"2011","unstructured":"Siegel R, Ward E, Brawley O, Jemal A. Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin. 2011, 61:212-36. 10.3322\/caac.20121","journal-title":"CA Cancer J Clin"},{"key":"ref2","unstructured":"The FDA recommends against using screening tests for ovarian cancer screening. FDA safety communication. (2016). https:\/\/www.moph.gov.lb\/userfiles\/files\/Medical%20Devices\/Medical%20Devices%20Recalls%202016\/5-9-2016\/OvarianCancerSc...."},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2017.21926","article-title":"Screening for ovarian cancer: US preventive services task force recommendation statement","volume":"319","author":"Grossman DC","year":"2018","unstructured":"Grossman DC, Curry SJ, Owens DK, et al.. Screening for ovarian cancer: US preventive services task force recommendation statement. JAMA. 2018, 319:588-94. 10.1001\/jama.2017.21926","journal-title":"JAMA"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.3892\/mco.2014.279","article-title":"Comparison of serum human epididymis protein 4 and carbohydrate antigen 125 as markers in ovarian cancer: a meta-analysis","volume":"2","author":"Zhen S","year":"2014","unstructured":"Zhen S, Bian LH, Chang LL, Gao X. Comparison of serum human epididymis protein 4 and carbohydrate antigen 125 as markers in ovarian cancer: a meta-analysis. Mol Clin Oncol. 2014, 2:559-66. 10.3892\/mco.2014.279","journal-title":"Mol Clin Oncol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2007.10.017","article-title":"The use of multiple novel tumor biomarkers for the detection of ovarian carcinoma in patients with a pelvic mass","volume":"108","author":"Moore RG","year":"2008","unstructured":"Moore RG, Brown AK, Miller MC, et al.. The use of multiple novel tumor biomarkers for the detection of ovarian carcinoma in patients with a pelvic mass. Gynecol Oncol. 2008, 108:402-8. 10.1016\/j.ygyno.2007.10.017","journal-title":"Gynecol Oncol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.22594","article-title":"Ovarian cancer screening with annual transvaginal sonography: findings of 25,000 women screened","volume":"109","author":"van Nagell JR Jr","year":"2007","unstructured":"van Nagell JR Jr, DePriest PD, Ueland FR, et al.. Ovarian cancer screening with annual transvaginal sonography: findings of 25,000 women screened. Cancer. 2007, 109:1887-96. 10.1002\/cncr.22594","journal-title":"Cancer"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.3390\/jpm11111115","article-title":"Biomarkers in ovarian pathology: from screening to diagnosis. Review of the literature","volume":"11","author":"Elorriaga M\u00c1","year":"2021","unstructured":"Elorriaga M\u00c1, Neyro JL, Mieza J, Crist\u00f3bal I, Llueca A. Biomarkers in ovarian pathology: from screening to diagnosis. Review of the literature. J Pers Med. 2021, 11:10.3390\/jpm11111115","journal-title":"J Pers Med"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1515\/cclm-2011-0477","article-title":"Diagnostic value of HE4 for ovarian cancer: a meta-analysis","volume":"50","author":"Yu S","year":"2012","unstructured":"Yu S, Yang HJ, Xie SQ, Bao YX. Diagnostic value of HE4 for ovarian cancer: a meta-analysis. Clin Chem Lab Med. 2012, 50:1439-46. 10.1515\/cclm-2011-0477","journal-title":"Clin Chem Lab Med"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1097\/IGC.0000000000000192","article-title":"Accuracy of serum human epididymis protein 4 in ovarian cancer diagnosis: a systematic review and meta-analysis","volume":"24","author":"Macedo AC","year":"2014","unstructured":"Macedo AC, da Rosa MI, Lumertz S, Medeiros LR. Accuracy of serum human epididymis protein 4 in ovarian cancer diagnosis: a systematic review and meta-analysis. Int J Gynecol Cancer. 2014, 24:1222-31. 10.1097\/IGC.0000000000000192","journal-title":"Int J Gynecol Cancer"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1136\/jclinpath-2012-201031","article-title":"Serum human epididymis protein 4 vs carbohydrate antigen 125 for ovarian cancer diagnosis: a systematic review","volume":"66","author":"Ferraro S","year":"2013","unstructured":"Ferraro S, Braga F, Lanzoni M, Boracchi P, Biganzoli EM, Panteghini M. Serum human epididymis protein 4 vs carbohydrate antigen 125 for ovarian cancer diagnosis: a systematic review. J Clin Pathol. 2013, 66:273-81. 10.1136\/jclinpath-2012-201031","journal-title":"J Clin Pathol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1097\/IGC.0000000000000804","article-title":"Diagnostic performance of risk of ovarian malignancy algorithm against CA125 and HE4 in connection with ovarian cancer: a meta-analysis","volume":"26","author":"Dayyani F","year":"2016","unstructured":"Dayyani F, Uhlig S, Colson B, Simon K, Rolny V, Morgenstern D, Schlumbrecht M. Diagnostic performance of risk of ovarian malignancy algorithm against CA125 and HE4 in connection with ovarian cancer: a meta-analysis. Int J Gynecol Cancer. 2016, 26:1586-93. 10.1097\/IGC.0000000000000804","journal-title":"Int J Gynecol Cancer"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1007\/s13277-014-1811-6","article-title":"Diagnostic accuracy of serum HE4, CA125 and ROMA in patients with ovarian cancer: a meta-analysis","volume":"35","author":"Wang J","year":"2014","unstructured":"Wang J, Gao J, Yao H, Wu Z, Wang M, Qi J. Diagnostic accuracy of serum HE4, CA125 and ROMA in patients with ovarian cancer: a meta-analysis. Tumour Biol. 2014, 35:6127-38. 10.1007\/s13277-014-1811-6","journal-title":"Tumour Biol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1080\/14737140.2017.1360138","article-title":"The role of novel biomarker HE4 in the diagnosis, prognosis and follow-up of ovarian cancer: a systematic review","volume":"17","author":"Scaletta G","year":"2017","unstructured":"Scaletta G, Plotti F, Luvero D, et al.. The role of novel biomarker HE4 in the diagnosis, prognosis and follow-up of ovarian cancer: a systematic review. Expert Rev Anticancer Ther. 2017, 17:827-39. 10.1080\/14737140.2017.1360138","journal-title":"Expert Rev Anticancer Ther"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1097\/IGC.0b013e318263efa2","article-title":"Diagnostic value of serum human epididymis protein 4 (HE4) in ovarian carcinoma: a systematic review and meta-analysis","volume":"22","author":"Wu L","year":"2012","unstructured":"Wu L, Dai ZY, Qian YH, Shi Y, Liu FJ, Yang C. Diagnostic value of serum human epididymis protein 4 (HE4) in ovarian carcinoma: a systematic review and meta-analysis. Int J Gynecol Cancer. 2012, 22:1106-12. 10.1097\/IGC.0b013e318263efa2","journal-title":"Int J Gynecol Cancer"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejogrb.2012.10.036","article-title":"Human epididymis protein 4 for differential diagnosis between benign gynecologic disease and ovarian cancer: a systematic review and meta-analysis","volume":"167","author":"Lin J","year":"2013","unstructured":"Lin J, Qin J, Sangvatanakul V. Human epididymis protein 4 for differential diagnosis between benign gynecologic disease and ovarian cancer: a systematic review and meta-analysis. Eur J Obstet Gynecol Reprod Biol. 2013, 167:81-5. 10.1016\/j.ejogrb.2012.10.036","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejogrb.2018.10.008","article-title":"Diagnostic value of HE4 in ovarian cancer: a meta-analysis","volume":"231","author":"Huang J","year":"2018","unstructured":"Huang J, Chen J, Huang Q. Diagnostic value of HE4 in ovarian cancer: a meta-analysis. Eur J Obstet Gynecol Reprod Biol. 2018, 231:35-42. 10.1016\/j.ejogrb.2018.10.008","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"ref17","unstructured":"Cochrane handbook for systematic reviews of diagnostic test accuracy. (2010). https.\/\/methods.cochrane.org\/sdt\/sites\/methods.cochrane.org.sdt\/files\/uploads\/Chapter%2010%20-%20Version%201.0.pdf."},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2017.19163","article-title":"Preferred Reporting Items for a Systematic Review and Meta-analysis of diagnostic test accuracy studies: the PRISMA-DTA statement","volume":"319","author":"McInnes MD","year":"2018","unstructured":"McInnes MD, Moher D, Thombs BD, et al.. Preferred Reporting Items for a Systematic Review and Meta-analysis of diagnostic test accuracy studies: the PRISMA-DTA statement. JAMA. 2018, 319:388-96. 10.1001\/jama.2017.19163","journal-title":"JAMA"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-155-8-201110180-00009","article-title":"QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies","volume":"155","author":"Whiting PF","year":"2011","unstructured":"Whiting PF, Rutjes AW, Westwood ME, et al.. QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies. Ann Intern Med. 2011, 155:529-36. 10.7326\/0003-4819-155-8-201110180-00009","journal-title":"Ann Intern Med"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2407-13-423","article-title":"Symptoms, CA125 and HE4 for the preoperative prediction of ovarian malignancy in Brazilian women with ovarian masses","volume":"13","author":"Pitta Dda R","year":"2013","unstructured":"Pitta Dda R, Sarian LO, Barreta A, et al.. Symptoms, CA125 and HE4 for the preoperative prediction of ovarian malignancy in Brazilian women with ovarian masses. BMC Cancer. 2013, 13:423. 10.1186\/1471-2407-13-423","journal-title":"BMC Cancer"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.31557\/APJCP.2019.20.4.1103","article-title":"Diagnostic performance of serum human epididymis protein 4 (HE4) for prediction of malignancy in ovarian masses","volume":"20","author":"Dewan R","year":"2019","unstructured":"Dewan R, Dewan A, Jindal M, Bhardawaj M. Diagnostic performance of serum human epididymis protein 4 (HE4) for prediction of malignancy in ovarian masses. Asian Pac J Cancer Prev. 2019, 20:1103-8. 10.31557\/APJCP.2019.20.4.1103","journal-title":"Asian Pac J Cancer Prev"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1016\/j.cca.2014.11.013","article-title":"Development of a multimarker assay for differential diagnosis of benign and malignant pelvic masses","volume":"440","author":"Chen X","year":"2015","unstructured":"Chen X, Zhou H, Chen R, et al.. Development of a multimarker assay for differential diagnosis of benign and malignant pelvic masses. Clin Chim Acta. 2015, 440:57-63. 10.1016\/j.cca.2014.11.013","journal-title":"Clin Chim Acta"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.2478\/s11536-013-0218-x","article-title":"Diagnostic value of serum tumor markers evaluation for adnexal masses","volume":"9","author":"Terzic MM","year":"2014","unstructured":"Terzic MM, Dotlic J, Likic I, et al.. Diagnostic value of serum tumor markers evaluation for adnexal masses. Cent Eur J Med. 2014, 9:210-6. 10.2478\/s11536-013-0218-x","journal-title":"Cent Eur J Med"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1016\/j.cca.2017.05.029","article-title":"Performance of ROMA based on Architect CA 125 II and HE4 values in Chinese women presenting with a pelvic mass: a multicenter prospective study","volume":"471","author":"Shen F","year":"2017","unstructured":"Shen F, Lu S, Peng Y, et al.. Performance of ROMA based on Architect CA 125 II and HE4 values in Chinese women presenting with a pelvic mass: a multicenter prospective study. Clin Chim Acta. 2017, 471:119-25. 10.1016\/j.cca.2017.05.029","journal-title":"Clin Chim Acta"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1158\/1055-9965.EPI-11-0635","article-title":"Serum human epididymis protein 4 and risk for ovarian malignancy algorithm as new diagnostic and prognostic tools for epithelial ovarian cancer management","volume":"20","author":"Bandiera E","year":"2011","unstructured":"Bandiera E, Romani C, Specchia C, et al.. Serum human epididymis protein 4 and risk for ovarian malignancy algorithm as new diagnostic and prognostic tools for epithelial ovarian cancer management. Cancer Epidemiol Biomarkers Prev. 2011, 20:2496-506. 10.1158\/1055-9965.EPI-11-0635","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1186\/1757-2215-6-45","article-title":"The plasma concentration of VEGF, HE4 and CA125 as a new biomarkers panel in different stages and sub-types of epithelial ovarian tumors","volume":"6","author":"Lawicki S","year":"2013","unstructured":"Lawicki S, B\u0119dkowska GE, Gacuta-Szumarska E, Szmitkowski M. The plasma concentration of VEGF, HE4 and CA125 as a new biomarkers panel in different stages and sub-types of epithelial ovarian tumors. J Ovarian Res. 2013, 6:45. 10.1186\/1757-2215-6-45","journal-title":"J Ovarian Res"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1155\/2018\/5289804","article-title":"Does the risk of ovarian malignancy algorithm provide better diagnostic performance than HE4 and CA125 in the presurgical differentiation of adnexal tumors in Polish women?","volume":"2018","author":"Abdalla N","year":"2018","unstructured":"Abdalla N, Piorkowski R, Bachanek M, Stanirowski P, Cendrowski K, Sawicki W. Does the risk of ovarian malignancy algorithm provide better diagnostic performance than HE4 and CA125 in the presurgical differentiation of adnexal tumors in Polish women?. Dis Markers. 2018, 2018:5289804. 10.1155\/2018\/5289804","journal-title":"Dis Markers"},{"key":"ref28","article-title":"HE4 and mesothelin: novel biomarkers of ovarian carcinoma in patients with pelvic masses","volume":"11","author":"Abdel-Azeez HA","year":"2010","unstructured":"Abdel-Azeez HA, Labib HA, Sharaf SM, Refaie AN. HE4 and mesothelin: novel biomarkers of ovarian carcinoma in patients with pelvic masses. Asian Pac J Cancer Prev. 2010, 11:111-6.","journal-title":"Asian Pac J Cancer Prev"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1016\/j.currproblcancer.2018.12.004","article-title":"Diagnostic accuracy of CA125 and HE4 in ovarian carcinoma patients and the effect of confounders on their serum levels","volume":"43","author":"Ahmed AA","year":"2019","unstructured":"Ahmed AA, Abdou AM. Diagnostic accuracy of CA125 and HE4 in ovarian carcinoma patients and the effect of confounders on their serum levels. Curr Probl Cancer. 2019, 43:450-60. 10.1016\/j.currproblcancer.2018.12.004","journal-title":"Curr Probl Cancer"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1016\/j.jogoh.2020.101713","article-title":"Comparison of HE 4, CA 125, ROMA score and ultrasound score in the differential diagnosis of ovarian masses","volume":"49","author":"Aslan K","year":"2020","unstructured":"Aslan K, Onan MA, Yilmaz C, Bukan N, Erdem M. Comparison of HE 4, CA 125, ROMA score and ultrasound score in the differential diagnosis of ovarian masses. J Gynecol Obstet Hum Reprod. 2020, 49:101713. 10.1016\/j.jogoh.2020.101713","journal-title":"J Gynecol Obstet Hum Reprod"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1155\/2018\/7821574","article-title":"Assessment of diagnostic values among CA-125, RMI, HE4, and ROMA for cancer prediction in women with nonfunctional ovarian cysts","volume":"2018","author":"Oranratanaphan S","year":"2018","unstructured":"Oranratanaphan S, Wanishpongpan S, Termrungruanglert W, Triratanachat S. Assessment of diagnostic values among CA-125, RMI, HE4, and ROMA for cancer prediction in women with nonfunctional ovarian cysts. Obstet Gynecol Int. 2018, 2018:7821574. 10.1155\/2018\/7821574","journal-title":"Obstet Gynecol Int"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1007\/s40944-017-0168-3","article-title":"A comparative study of RMI and ROMA in women presenting with an adnexal mass","volume":"16","author":"Priyanka V","year":"2017","unstructured":"Priyanka V, Karthiga S, Sivanesan B, Jagadeesan N, Balasubramani L. A comparative study of RMI and ROMA in women presenting with an adnexal mass. Indian J Gynecol Oncol. 2017, 16:1-6. 10.1007\/s40944-017-0168-3","journal-title":"Indian J Gynecol Oncol"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.3802\/jgo.2015.26.1.46","article-title":"Distinguishing benign from malignant pelvic mass utilizing an algorithm with HE4, menopausal status, and ultrasound findings","volume":"26","author":"Wilailak S","year":"2015","unstructured":"Wilailak S, Chan KK, Chen CA, et al.. Distinguishing benign from malignant pelvic mass utilizing an algorithm with HE4, menopausal status, and ultrasound findings. J Gynecol Oncol. 2015, 26:46-53. 10.3802\/jgo.2015.26.1.46","journal-title":"J Gynecol Oncol"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.3892\/br.2016.682","article-title":"The diagnostic value of serum HE4 and CA-125 and ROMA index in ovarian cancer","volume":"5","author":"Wei SU","year":"2016","unstructured":"Wei SU, Li H, Zhang B. The diagnostic value of serum HE4 and CA-125 and ROMA index in ovarian cancer. Biomed Rep. 2016, 5:41-4. 10.3892\/br.2016.682","journal-title":"Biomed Rep"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1159\/000446238","article-title":"Is the risk of ovarian malignancy algorithm better than other tests for predicting ovarian malignancy in women with pelvic masses?","volume":"82","author":"Yanaranop M","year":"2017","unstructured":"Yanaranop M, Anakrat V, Siricharoenthai S, Nakrangsee S, Thinkhamrop B. Is the risk of ovarian malignancy algorithm better than other tests for predicting ovarian malignancy in women with pelvic masses?. Gynecol Obstet Invest. 2017, 82:47-53. 10.1159\/000446238","journal-title":"Gynecol Obstet Invest"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1002\/uog.12551","article-title":"Are serum HE4 or ROMA scores useful to experienced examiners for improving characterization of adnexal masses after transvaginal ultrasonography?","volume":"43","author":"Kaijser J","year":"2014","unstructured":"Kaijser J, Van Gorp T, Smet ME, et al.. Are serum HE4 or ROMA scores useful to experienced examiners for improving characterization of adnexal masses after transvaginal ultrasonography?. Ultrasound Obstet Gynecol. 2014, 43:89-97. 10.1002\/uog.12551","journal-title":"Ultrasound Obstet Gynecol"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2017.08.020","article-title":"Combining a symptom index, CA125 and HE4 (triple screen) to detect ovarian cancer in women with a pelvic mass","volume":"147","author":"Goff BA","year":"2017","unstructured":"Goff BA, Agnew K, Neradilek MB, Gray HJ, Liao JB, Urban RR. Combining a symptom index, CA125 and HE4 (triple screen) to detect ovarian cancer in women with a pelvic mass. Gynecol Oncol. 2017, 147:291-5. 10.1016\/j.ygyno.2017.08.020","journal-title":"Gynecol Oncol"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinbiochem.2011.04.011","article-title":"Diagnostic performances of HE4 and CA125 for the detection of ovarian cancer from patients with various gynecologic and non-gynecologic diseases","volume":"44","author":"Park Y","year":"2011","unstructured":"Park Y, Lee JH, Hong DJ, Lee EY, Kim HS. Diagnostic performances of HE4 and CA125 for the detection of ovarian cancer from patients with various gynecologic and non-gynecologic diseases. Clin Biochem. 2011, 44:884-8. 10.1016\/j.clinbiochem.2011.04.011","journal-title":"Clin Biochem"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2010.02.005","article-title":"Serum biomarker panels for the discrimination of benign from malignant cases in patients with an adnexal mass","volume":"117","author":"Nolen B","year":"2010","unstructured":"Nolen B, Velikokhatnaya L, Marrangoni A, De Geest K, Lomakin A, Bast RC Jr, Lokshin A. Serum biomarker panels for the discrimination of benign from malignant cases in patients with an adnexal mass. Gynecol Oncol. 2010, 117:440-5. 10.1016\/j.ygyno.2010.02.005","journal-title":"Gynecol Oncol"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2011.02.022","article-title":"No benefit from combining HE4 and CA125 as ovarian tumor markers in a clinical setting","volume":"121","author":"Jacob F","year":"2011","unstructured":"Jacob F, Meier M, Caduff R, et al.. No benefit from combining HE4 and CA125 as ovarian tumor markers in a clinical setting. Gynecol Oncol. 2011, 121:487-91. 10.1016\/j.ygyno.2011.02.022","journal-title":"Gynecol Oncol"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.1007\/s13277-009-0015-y","article-title":"HE4: a new potential early biomarker for the recurrence of ovarian cancer","volume":"31","author":"Anastasi E","year":"2010","unstructured":"Anastasi E, Marchei GG, Viggiani V, Gennarini G, Frati L, Reale MG. HE4: a new potential early biomarker for the recurrence of ovarian cancer. Tumour Biol. 2010, 31:113-9. 10.1007\/s13277-009-0015-y","journal-title":"Tumour Biol"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2009.10.087","article-title":"Use of a symptom index, CA125, and HE4 to predict ovarian cancer","volume":"116","author":"Andersen MR","year":"2010","unstructured":"Andersen MR, Goff BA, Lowe KA, et al.. Use of a symptom index, CA125, and HE4 to predict ovarian cancer. Gynecol Oncol. 2010, 116:378-83. 10.1016\/j.ygyno.2009.10.087","journal-title":"Gynecol Oncol"},{"key":"ref43","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6606092","article-title":"HE4 and CA125 as a diagnostic test in ovarian cancer: prospective validation of the Risk of Ovarian Malignancy Algorithm","volume":"104","author":"Van Gorp T","year":"2011","unstructured":"Van Gorp T, Cadron I, Despierre E, et al.. HE4 and CA125 as a diagnostic test in ovarian cancer: prospective validation of the Risk of Ovarian Malignancy Algorithm. Br J Cancer. 2011, 104:863-70. 10.1038\/sj.bjc.6606092","journal-title":"Br J Cancer"},{"key":"ref44","doi-asserted-by":"publisher","DOI":"10.1097\/IGC.0b013e31821a3726","article-title":"Human epididymis protein 4 (HE4) as a serum tumor biomarker in patients with ovarian carcinoma","volume":"21","author":"Chang X","year":"2011","unstructured":"Chang X, Ye X, Dong L, et al.. Human epididymis protein 4 (HE4) as a serum tumor biomarker in patients with ovarian carcinoma. Int J Gynecol Cancer. 2011, 21:852-8. 10.1097\/IGC.0b013e31821a3726","journal-title":"Int J Gynecol Cancer"},{"key":"ref45","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajog.2011.05.017","article-title":"Human epididymis protein 4 offers superior specificity in the differentiation of benign and malignant adnexal masses in premenopausal women","volume":"205","author":"Holcomb K","year":"2011","unstructured":"Holcomb K, Vucetic Z, Miller MC, Knapp RC. Human epididymis protein 4 offers superior specificity in the differentiation of benign and malignant adnexal masses in premenopausal women. Am J Obstet Gynecol. 2011, 205:358.e1-6. 10.1016\/j.ajog.2011.05.017","journal-title":"Am J Obstet Gynecol"},{"key":"ref46","doi-asserted-by":"publisher","DOI":"10.1515\/CCLM.2011.075","article-title":"The ROMA (Risk of Ovarian Malignancy Algorithm) for estimating the risk of epithelial ovarian cancer in women presenting with pelvic mass: is it really useful?","volume":"49","author":"Montagnana M","year":"2011","unstructured":"Montagnana M, Danese E, Ruzzenente O, et al.. The ROMA (Risk of Ovarian Malignancy Algorithm) for estimating the risk of epithelial ovarian cancer in women presenting with pelvic mass: is it really useful?. Clin Chem Lab Med. 2011, 49:521-5. 10.1515\/CCLM.2011.075","journal-title":"Clin Chem Lab Med"},{"key":"ref47","article-title":"[The values of serum human epididymis secretory protein 4 and CA(125) assay in the diagnosis of ovarian malignancy] (Article in Chinese)","volume":"43","author":"Dong L","year":"2008","unstructured":"Dong L, Cheng XH, Ye X, et al.. [The values of serum human epididymis secretory protein 4 and CA(125) assay in the diagnosis of ovarian malignancy] (Article in Chinese). Zhonghua Fu Chan Ke Za Zhi. 2008, 43:931-6.","journal-title":"Zhonghua Fu Chan Ke Za Zhi"},{"key":"ref48","article-title":"Evaluation of HE4, CA125 as a diagnostic tools in the differential diagnosis of ovarian cancer in Albanian women","volume":"8","author":"Mitre A","year":"2020","unstructured":"Mitre A, Qirinxhi X. Evaluation of HE4, CA125 as a diagnostic tools in the differential diagnosis of ovarian cancer in Albanian women. Int J Adv Sci Eng Technol. 2020, 8:86-90.","journal-title":"Int J Adv Sci Eng Technol"},{"key":"ref49","doi-asserted-by":"publisher","DOI":"10.1186\/1746-1596-8-11","article-title":"Significance of HE4 estimation in comparison with CA125 in diagnosis of ovarian cancer and assessment of treatment response","volume":"8","author":"Hamed EO","year":"2013","unstructured":"Hamed EO, Ahmed H, Sedeek OB, Mohammed AM, Abd-Alla AA, Abdel Ghaffar HM. Significance of HE4 estimation in comparison with CA125 in diagnosis of ovarian cancer and assessment of treatment response. Diagn Pathol. 2013, 8:11. 10.1186\/1746-1596-8-11","journal-title":"Diagn Pathol"},{"key":"ref50","doi-asserted-by":"publisher","DOI":"10.6061\/clinics\/2012(05)06","article-title":"A comparison of CA125, HE4, risk ovarian malignancy algorithm (ROMA), and risk malignancy index (RMI) for the classification of ovarian masses","volume":"67","author":"Anton C","year":"2012","unstructured":"Anton C, Carvalho FM, Oliveira EI, Maciel GA, Baracat EC, Carvalho JP. A comparison of CA125, HE4, risk ovarian malignancy algorithm (ROMA), and risk malignancy index (RMI) for the classification of ovarian masses. Clinics (Sao Paulo). 2012, 67:437-41. 10.6061\/clinics\/2012(05)06","journal-title":"Clinics (Sao Paulo)"},{"key":"ref51","doi-asserted-by":"publisher","DOI":"10.1007\/s13277-014-1945-6","article-title":"HE4, Ca125 and ROMA algorithm for differential diagnosis between benign gynaecological diseases and ovarian cancer","volume":"35","author":"Ortiz-Mu\u00f1oz B","year":"2014","unstructured":"Ortiz-Mu\u00f1oz B, Aznar-Oroval E, Garc\u00eda Garc\u00eda A, et al.. HE4, Ca125 and ROMA algorithm for differential diagnosis between benign gynaecological diseases and ovarian cancer. Tumour Biol. 2014, 35:7249-58. 10.1007\/s13277-014-1945-6","journal-title":"Tumour Biol"},{"key":"ref52","doi-asserted-by":"publisher","DOI":"10.1007\/s13277-011-0204-3","article-title":"HE4 a novel tumour marker for ovarian cancer: comparison with CA 125 and ROMA algorithm in patients with gynaecological diseases","volume":"32","author":"Molina R","year":"2011","unstructured":"Molina R, Escudero JM, Aug\u00e9 JM, et al.. HE4 a novel tumour marker for ovarian cancer: comparison with CA 125 and ROMA algorithm in patients with gynaecological diseases. Tumour Biol. 2011, 32:1087-95. 10.1007\/s13277-011-0204-3","journal-title":"Tumour Biol"},{"key":"ref53","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2012.07.106","article-title":"Evaluation of HE4, CA125, risk of ovarian malignancy algorithm (ROMA) and risk of malignancy index (RMI) as diagnostic tools of epithelial ovarian cancer in patients with a pelvic mass","volume":"127","author":"Karlsen MA","year":"2012","unstructured":"Karlsen MA, Sandhu N, H\u00f8gdall C, et al.. Evaluation of HE4, CA125, risk of ovarian malignancy algorithm (ROMA) and risk of malignancy index (RMI) as diagnostic tools of epithelial ovarian cancer in patients with a pelvic mass. Gynecol Oncol. 2012, 127:379-83. 10.1016\/j.ygyno.2012.07.106","journal-title":"Gynecol Oncol"},{"key":"ref54","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajog.2019.07.031","article-title":"Serum HE4 and diagnosis of ovarian cancer in postmenopausal women with adnexal masses","volume":"222","author":"Gentry-Maharaj A","year":"2020","unstructured":"Gentry-Maharaj A, Burnell M, Dilley J, et al.. Serum HE4 and diagnosis of ovarian cancer in postmenopausal women with adnexal masses. Am J Obstet Gynecol. 2020, 222:56.e1-56.e17. 10.1016\/j.ajog.2019.07.031","journal-title":"Am J Obstet Gynecol"},{"key":"ref55","doi-asserted-by":"publisher","DOI":"10.1016\/j.cca.2011.04.028","article-title":"HE4 and epithelial ovarian cancer: comparison and clinical evaluation of two immunoassays and a combination algorithm","volume":"412","author":"Ruggeri G","year":"2011","unstructured":"Ruggeri G, Bandiera E, Zanotti L, et al.. HE4 and epithelial ovarian cancer: comparison and clinical evaluation of two immunoassays and a combination algorithm. Clin Chim Acta. 2011, 412:1447-53. 10.1016\/j.cca.2011.04.028","journal-title":"Clin Chim Acta"},{"key":"ref56","doi-asserted-by":"publisher","DOI":"10.1515\/CCLM.2011.709","article-title":"The diagnostic accuracy of two human epididymis protein 4 (HE4) testing systems in combination with CA125 in the differential diagnosis of ovarian masses","volume":"49","author":"Lenhard M","year":"2011","unstructured":"Lenhard M, Stieber P, Hertlein L, et al.. The diagnostic accuracy of two human epididymis protein 4 (HE4) testing systems in combination with CA125 in the differential diagnosis of ovarian masses. Clin Chem Lab Med. 2011, 49:2081-8. 10.1515\/CCLM.2011.709","journal-title":"Clin Chem Lab Med"},{"key":"ref57","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2015.03.044","article-title":"Detection of the HE4 protein in urine as a biomarker for ovarian neoplasms: clinical correlates","volume":"137","author":"Liao JB","year":"2015","unstructured":"Liao JB, Yip YY, Swisher EM, Agnew K, Hellstrom KE, Hellstrom I. Detection of the HE4 protein in urine as a biomarker for ovarian neoplasms: clinical correlates. Gynecol Oncol. 2015, 137:430-5. 10.1016\/j.ygyno.2015.03.044","journal-title":"Gynecol Oncol"},{"key":"ref58","doi-asserted-by":"publisher","DOI":"10.3892\/br.2017.913","article-title":"Diagnostic value of urinary-to-serum human epididymis protein 4 ratio in ovarian cancer","volume":"7","author":"Fan Q","year":"2017","unstructured":"Fan Q, Luo G, Yi T, et al.. Diagnostic value of urinary-to-serum human epididymis protein 4 ratio in ovarian cancer. Biomed Rep. 2017, 7:67-72. 10.3892\/br.2017.913","journal-title":"Biomed Rep"},{"key":"ref59","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2010.03.013","article-title":"Detection of the HE4 protein in urine as a biomarker for ovarian neoplasms","volume":"296","author":"Hellstrom I","year":"2010","unstructured":"Hellstrom I, Heagerty PJ, Swisher EM, Liu P, Jaffar J, Agnew K, Hellstrom KE. Detection of the HE4 protein in urine as a biomarker for ovarian neoplasms. Cancer Lett. 2010, 296:43-8. 10.1016\/j.canlet.2010.03.013","journal-title":"Cancer Lett"},{"key":"ref60","doi-asserted-by":"publisher","DOI":"10.7314\/apjcp.2012.13.9.4695","article-title":"Urinary concentrations of human epidydimis secretory protein 4 (He4) in the diagnosis of ovarian cancer: a case--control study","volume":"13","author":"Macuks R","year":"2012","unstructured":"Macuks R, Baidekalna I, Donina S. Urinary concentrations of human epidydimis secretory protein 4 (He4) in the diagnosis of ovarian cancer: a case--control study. Asian Pac J Cancer Prev. 2012, 13:4695-8. 10.7314\/apjcp.2012.13.9.4695","journal-title":"Asian Pac J Cancer Prev"},{"key":"ref61","doi-asserted-by":"publisher","DOI":"10.1039\/c1lc20479c","article-title":"Integration of cell phone imaging with microchip ELISA to detect ovarian cancer HE4 biomarker in urine at the point-of-care","volume":"11","author":"Wang S","year":"2011","unstructured":"Wang S, Zhao X, Khimji I, et al.. Integration of cell phone imaging with microchip ELISA to detect ovarian cancer HE4 biomarker in urine at the point-of-care. Lab Chip. 2011, 11:3411-8. 10.1039\/c1lc20479c","journal-title":"Lab Chip"},{"key":"ref62","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-04-3924","article-title":"Human epididymis protein 4 (HE4) is a secreted glycoprotein that is overexpressed by serous and endometrioid ovarian carcinomas","volume":"65","author":"Drapkin R","year":"2005","unstructured":"Drapkin R, von Horsten HH, Lin Y, Mok SC, Crum CP, Welch WR, Hecht JL. Human epididymis protein 4 (HE4) is a secreted glycoprotein that is overexpressed by serous and endometrioid ovarian carcinomas. Cancer Res. 2005, 65:2162-9. 10.1158\/0008-5472.CAN-04-3924","journal-title":"Cancer Res"},{"key":"ref63","doi-asserted-by":"publisher","DOI":"10.1038\/modpathol.3800612","article-title":"Comprehensive analysis of HE4 expression in normal and malignant human tissues","volume":"19","author":"Galgano MT","year":"2006","unstructured":"Galgano MT, Hampton GM, Frierson HF Jr. Comprehensive analysis of HE4 expression in normal and malignant human tissues. Mod Pathol. 2006, 19:847-53. 10.1038\/modpathol.3800612","journal-title":"Mod Pathol"},{"key":"ref64","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-96552-9","article-title":"Diagnostic measures comparison for ovarian malignancy risk in epithelial ovarian cancer patients: a meta-analysis","volume":"11","author":"Suri A","year":"2021","unstructured":"Suri A, Perumal V, Ammalli P, Suryan V, Bansal SK. Diagnostic measures comparison for ovarian malignancy risk in epithelial ovarian cancer patients: a meta-analysis. Sci Rep. 2021, 11:17308. 10.1038\/s41598-021-96552-9","journal-title":"Sci Rep"},{"key":"ref65","doi-asserted-by":"publisher","DOI":"10.1186\/s13048-019-0503-7","article-title":"Biomarkers and algorithms for diagnosis of ovarian cancer: CA125, HE4, RMI and ROMA, a review","volume":"12","author":"Dochez V","year":"2019","unstructured":"Dochez V, Caillon H, Vaucel E, Dimet J, Winer N, Ducarme G. Biomarkers and algorithms for diagnosis of ovarian cancer: CA125, HE4, RMI and ROMA, a review. J Ovarian Res. 2019, 12:28. 10.1186\/s13048-019-0503-7","journal-title":"J Ovarian Res"},{"key":"ref66","doi-asserted-by":"publisher","DOI":"10.1016\/j.cca.2014.11.015","article-title":"ROMA, an algorithm for ovarian cancer","volume":"440","author":"Chudecka-G\u0142az AM","year":"2015","unstructured":"Chudecka-G\u0142az AM. ROMA, an algorithm for ovarian cancer. Clin Chim Acta. 2015, 440:143-51. 10.1016\/j.cca.2014.11.015","journal-title":"Clin Chim Acta"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/115306-the-diagnostic-accuracy-of-serum-and-urine-human-epididymis-protein-4-he4-in-ovarian-cancer-in-15394-subjects-an-updated-meta-analysis","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:52:14Z","timestamp":1707508334000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/115306-the-diagnostic-accuracy-of-serum-and-urine-human-epididymis-protein-4-he4-in-ovarian-cancer-in-15394-subjects-an-updated-meta-analysis"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,19]]},"references-count":66,"URL":"https:\/\/doi.org\/10.7759\/cureus.30457","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2022,10,19]]}}}